Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Gilles SallesJenny M H ChenIna ZhangFabio KerbauyJames J WuSally W WadeAna NunesChaoling FengIoana KloosWeimin PengJulia T SniderDylan MacielKeith ChanSam KeepingBijal ShahPublished in: Advances in therapy (2024)
Findings suggest that brexu-cel may offer clinically and statistically significant benefits regarding objective response, complete response, and progression-free survival compared to pirtobrutinib among patients with R/R MCL after prior cBTKi therapy. Given the short follow-up and high degree of censoring in BRUIN, an analysis incorporating updated BRUIN data may provide more definitive overall survival results.
Keyphrases
- free survival
- acute lymphoblastic leukemia
- acute myeloid leukemia
- electronic health record
- hodgkin lymphoma
- multiple myeloma
- diffuse large b cell lymphoma
- big data
- locally advanced
- stem cells
- radiation therapy
- squamous cell carcinoma
- newly diagnosed
- mesenchymal stem cells
- cell therapy
- rectal cancer
- smoking cessation
- clinical evaluation
- chemotherapy induced